ES2573291T3 - Utilización de luz verde para activar la L-aminoácido oxidasa - Google Patents

Utilización de luz verde para activar la L-aminoácido oxidasa Download PDF

Info

Publication number
ES2573291T3
ES2573291T3 ES08826887.5T ES08826887T ES2573291T3 ES 2573291 T3 ES2573291 T3 ES 2573291T3 ES 08826887 T ES08826887 T ES 08826887T ES 2573291 T3 ES2573291 T3 ES 2573291T3
Authority
ES
Spain
Prior art keywords
green light
amino acid
acid oxidase
activate
oxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08826887.5T
Other languages
English (en)
Inventor
Julien Laboureau
Quang Lan Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of ES2573291T3 publication Critical patent/ES2573291T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0654—Lamps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A61N5/0617—Hair treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización no terapéutica de una luz verde de longitud de onda comprendida entre 500 y 580 nm para activar la Laminoácido oxidasa en presencia de al menos uno de sus sustratos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
Pesar 34,8 mg de isoluminol y solubilizarlos bajo agitación magnética en aproximadamente 50 ml de 100 mM de tampón Borato. Pesar 2 mg de microperoxidasa y solubilizarlos bajo agitación magnética en aproximadamente 5 ml de 100 mM de tampón Borato. Los dos reactivos son entonces mezclados en un frasco con medidor de 200 ml cuyo
5 volumen se ajusta por un tampón Borato (aclarar 3 veces cada vaso de precipitado con tampón). Los 200 ml se colocan en un frasco de 500 ml. Se añaden entonces de nuevo 200 ml de tampón borato. La mezcla de reacción, cuyo volumen final es entonces de 400 ml se homogeneiza por agitación magnética y después se coloca en la oscuridad a temperatura ambiente al menos 24 horas antes del uso.
10 La lectura de luminiscencia se realiza con la ayuda del luminómetro "Fluoroskan Ascent FL" de Thermo Labsystems.
Resultados: Activación enzimática específica de la L-aminoácido oxidasa
-Influencia de la luz verde sobre la D-aminoácido oxidasa 15 D-amino oxidasa
Condición
Control Luz verde
Luminiscencia
577,5 568,2166667
-Influencia de la luz verde sobre la L-aminoácido oxidasa. L-aminoácido oxidasa
Condición
Control Luz verde
Luminiscencia
342,26667 409,8777778
Conclusión
25 Una exposición prolongada a la luz verde no modifica la actividad de la D-aminoácido oxidasa de manera significativa. Por el contrario, se observa que una exposición de 60 minutos induce una activación específica de la Lamino oxidasa.
30 Ejemplo 2 -Cinética de activación de la L-aminoácido oxidasa
Se realizan varias mediciones después de diferentes tiempos de exposición según el protocolo descrito en el ejemplo 1 y se resumen en la tabla siguiente:
35 Los resultados aparecen en la tabla siguiente y son representados en la figura 3 (la L-aminoácido oxidasa sensibilizada es la expuesta a la luz verde).
Tiempo de análisis
Control Luz verde
0
0
0,0
10
191,56667 248,0
20
349,66667 420,8
30
502,6 586,5
40
646,46667 735,2
50
756,26667 844,0
60
876,36667 970,9
Conclusión 40 La cinética de activación de la L-aminoácido oxidasa se aumenta por una exposición a la luz entre 500-560 nm.
Ejemplo 3 -activación de la L-aminoácido oxidasa según el tiempo de exposición: efecto dosis respuesta.
45 El ensayo se realiza en las mismas condiciones experimentales que en el ejemplo 1 siguiendo el protocolo del proveedor.
8
Tiempo de estimulación
Control Luz verde Diferencia
0
0
0,0
0
30
409,9 412,8 0,7
60
349,7 420,8 16,9
120
275,4 361,7 23,8
Los resultados aparecen en la tabla siguiente y se representan en la figura 4. 5 Conclusión Se constata que cuanto más larga sea la exposición de la enzima, más importante es su actividad. El diagrama siguiente muestra la relación entre la actividad de la enzima expuesta y la de la enzima control. 10 Ejemplo 4 -Composiciones
Crema de regeneración epidérmica (emulsión aceite en agua)
Poliacrildimetiltauramida de amonio (Hostacerin AMPS de Clariant)
1,00%
Ciclohexasiloxano
5,0%
Glicerina
1,70%
Alcohol estearílico
0,30%
Estearato de glicerilo / PEG-100 estearato
0,70%
Dimiristil tartrato / alcohol cetearílico / C12-15 pareth-7 / PPG-25 laureth-25
0,50%
Goma de Xantana
0,20%
L-Alanina
0,5%
Conservantes
0,50%
Agua
csp 100
Crema de regeneración epidérmica (emulsión aceite en agua)
Poliacrildimetiltauramida de amonio (Hostacerin AMPS de Clariant)
1,00%
Ciclohexasiloxano
5,0%
Glicerina
1,70%
Alcohol estearílico
0,30%
Estearato de glicerilo / PEG-100 estearato
0,70%
Dimiristil tartrato / alcohol cetearílico / C12-15 pareth-7 / PPG-25 laureth-25
0,50%
Goma de Xantana
0,20%
L-Leucina
0,5%
Conservantes
0,50%
Agua
csp 100
Se aplican estas cremas sobre la cara y/o sobre el cuerpo justo antes de una exposición prolongada (30 minutos a 15 1h30) bajo una radiación de longitud de onda comprendida entre 500 y 560 nm. Parche iontoforético Un parche de referencia comercial lontopatchTM (Travanti Pharma, Mendota Heights, MN, USA) se aplica sobre una 20 zona previamente tratada con una de las cremas anteriores. Después, se conecta a una corriente eléctrica para suministrar una corriente galvánica generada por una diferencia 9
de potencial de 1V y que comprende dos electrodos, un ánodo en Zn y un cátodo en AgCl y se expone a una fuente de luz verde.
Este tratamiento se realiza a razón de una vez por día durante 30 a 45 minutos. 5 Máscara verde
Fase oleosa: Octil-dodecanol 6% Aceite de hueso de albaricoque 6% Triglicéridos 5% Caolín 3% Alcohol cetílico 2% Acetato de vitamina E 0,5% Aceite de palma hidrogenado 6% Fracción líquida de manteca de karité 5% Fase acuosa: Goma de Xantana 0,4% Cocoato de sacarosa/estearato de sorbitán (mezcla vendida por la compañía société ICL bajo la 5,5%
denominación Arlaton 21121 Glicerina 3% Dipiridamol 0,30% Cobre clorofilina 0,20% Etanol 5% L_Alanina 0,5% Perfume 0,3% Conservante cs Agua csp100
Se aplica esta máscara sobre las zonas de la piel a tratar, después se coloca el sujeto debajo de una fuente de luz 10 blanca (natural o eléctrica) durante de 45 minutos a 1 hora.
10

Claims (1)

  1. imagen1
    imagen2
ES08826887.5T 2007-07-16 2008-07-16 Utilización de luz verde para activar la L-aminoácido oxidasa Active ES2573291T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0756506 2007-07-16
FR0756506A FR2918876B1 (fr) 2007-07-16 2007-07-16 Utilisation de lumiere verte pour activer la l-amino acide oxydase
US98245507P 2007-10-25 2007-10-25
US982455P 2007-10-25
PCT/FR2008/051333 WO2009019381A1 (fr) 2007-07-16 2008-07-16 Utilisation de lumiere verte pour activer la l-amino acide oxydase

Publications (1)

Publication Number Publication Date
ES2573291T3 true ES2573291T3 (es) 2016-06-07

Family

ID=39262624

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08826887.5T Active ES2573291T3 (es) 2007-07-16 2008-07-16 Utilización de luz verde para activar la L-aminoácido oxidasa

Country Status (6)

Country Link
US (1) US9750675B2 (es)
EP (1) EP2178496B1 (es)
JP (1) JP6214849B2 (es)
ES (1) ES2573291T3 (es)
FR (1) FR2918876B1 (es)
WO (1) WO2009019381A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976480B1 (fr) * 2011-06-14 2013-12-20 Oreal Procede de traitement cosmetique des matieres keratiniques
US9375439B2 (en) * 2013-01-09 2016-06-28 International Stem Cell Corporation Small molecules that promote skin regeneration
US20230121179A1 (en) * 2020-01-31 2023-04-20 Shiseido Company, Ltd. Skin barrier function enhancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR895680A (fr) * 1943-06-25 1945-01-31 Svenska Flaektfabriken Ab Perfectionnement au dispositif pour la mesure de la température
DE1980222U (de) * 1967-11-06 1968-03-07 Johannes Thoenes Stielbefestigung mittels verankerung im besen.
US4197316A (en) 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234691A (en) * 1978-02-27 1980-11-18 Yamasa Shoyu Kabushiki Kaisha L-Lysine α-oxidase
JPS56154990A (en) * 1980-04-30 1981-11-30 Toyo Jozo Co Ltd Preparation of l-aminoacid oxidase
US4614714A (en) * 1982-08-21 1986-09-30 Yamasa Shoyu Kabushiki Kaisha Use of novel L-glutamic acid oxidase
DE3333453A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt L-aminosaeure-oxidase aus hefen der gattung cryptococcus, ihre herstellung und verwendung
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5061480A (en) * 1989-11-03 1991-10-29 Marchese Co., Inc. Tanning composition
DK48893D0 (da) * 1993-04-30 1993-04-30 Novo Nordisk As Enzym
FR2729076B1 (fr) * 1995-01-09 1997-03-14 Thorel Jean Noel Milieu nutritif utilisable comme milieu de culture de cellules epidermiques et base nutritive a usage topique
EP0802784B1 (fr) * 1995-01-09 2000-12-13 Thorel, Jean-Noel Milieu nutritif utilisable comme milieu de culture de cellules epidermiques et applications
GB2370992B (en) * 2000-03-23 2002-11-20 Photo Therapeutics Ltd Therapeutic light source and method
US20030095959A1 (en) * 2000-11-21 2003-05-22 Access Business Group International Llc. Topical skin composition
EP1262168A1 (fr) * 2001-03-23 2002-12-04 L'oreal Composition pour lutter contre le vieillissement de la peau, contenant des fibres
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
TR201807182T4 (tr) * 2003-05-30 2018-06-21 De Paoli Ambrosi Gianfranco Kimyasal cilt/yüz soyma için olan formülasyonlarda dimetil sülfon kullanımı.
JP4398813B2 (ja) * 2003-07-18 2010-01-13 ヤーマン株式会社 美肌装置
DE102004041568A1 (de) * 2004-08-26 2006-03-09 Henkel Kgaa Zubereitung mit enzymatisch katalysierter Freisetzung von Pflegestoffen für keratinische Fasern in situ
DE102005024040A1 (de) * 2005-05-25 2006-12-14 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Kosmetisches oder therapeutisches Kombinationspräparat mit Theanin
FR2895680B1 (fr) * 2005-12-29 2011-03-18 Jean Noel Thorel Traitement therapeutique et/ou cosmetique d'une partie superficielle du corps humain, avec une base nutritive complexe
US20070255355A1 (en) * 2006-04-06 2007-11-01 Palomar Medical Technologies, Inc. Apparatus and method for skin treatment with compression and decompression

Also Published As

Publication number Publication date
US9750675B2 (en) 2017-09-05
EP2178496B1 (fr) 2016-03-16
EP2178496A1 (fr) 2010-04-28
WO2009019381A1 (fr) 2009-02-12
US20100228181A1 (en) 2010-09-09
JP2010533689A (ja) 2010-10-28
FR2918876B1 (fr) 2012-10-05
FR2918876A1 (fr) 2009-01-23
JP6214849B2 (ja) 2017-10-18

Similar Documents

Publication Publication Date Title
Chaiprasongsuk et al. Activation of Nrf2 reduces UVA-mediated MMP-1 upregulation via MAPK/AP-1 signaling cascades: the photoprotective effects of sulforaphane and hispidulin
Brown et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour‐bearing mice
Hwang et al. Muscle stem cells and aging
Lee et al. Cytotoxicity of chlorhexidine on human osteoblastic cells is related to intracellular glutathione levels
Al-Ahmad et al. Antimicrobial photodynamic therapy using visible light plus water-filtered infrared-A (wIRA)
AR012386A1 (es) Un cristal de proteina reticulado, y una composicion, un sistema de suministro de proteina y una formulacion que comprende dicho cristal.
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
ES2321200T3 (es) Una composicion de mascarilla cosmetica.
ES2573291T3 (es) Utilización de luz verde para activar la L-aminoácido oxidasa
Briso et al. Complications from the use of peroxides
Katiyar et al. Correlation of oxidative stress with melasma: an overview
US20220347068A1 (en) Bleaching Gel
Esteves Junior et al. Low-level laser irradiation, cyclooxygenase-2 (COX-2) expression and necrosis of random skin flaps in rats
Martins Andrade et al. Iontophoresis application for drug delivery in high resistivity membranes: nails and teeth
JP2011511049A (ja) 特に皮膚および／または髪の外観を改善するための、光線とチトクロームｃオキシダーゼ基質との組合せ
ES2729373T3 (es) Composición antifúngica tópica para tratar onicomicosis
Maghfour et al. Photobiomodulation CME Part I: Overview and Mechanism of Action
JP2019500109A (ja) ビタミンｃを送達するための、イオン泳動法、イオン泳動組成物、キットおよびイオン泳動デバイス
ES2795990T3 (es) Composiciones depilatorias
ES2978869T3 (es) Producto cosmético con propiedades reparadoras del ADN
CA3235710A1 (en) Topical compositions and methods for photodynamic therapy
CN114642733A (zh) 一种治疗雄激素源性脱发的组合物及其制备方法
Orasan et al. Minoxidil and neoptide topical application reinforced by low-level laser therapy on an animal model of alopecia
ES2884748T3 (es) Enjuague bucal a base de clorhexidina que previene las manchas de dientes
ES2902475T3 (es) Composición para la prevención de crecimiento microbiano